[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370495-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370495-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","solute-carrier-family-35-a2-slc35a2-promotes-tumor-progression-through-myc-mediated-pathways-in-colorectal-cancer","Solute Carrier Family 35 A2 (SLC35A2) Promotes Tumor Progression through MYC-Mediated Pathways in Colorectal Cancer","","Colorectal cancer (CRC) is a leading malignancy worldwide, and improved therapies still leave room for stronger responses in advanced disease. This study examines how dysregulated nucleotide sugar transporters (NSTs) influence CRC development and outcomes. Integrative bioinformatics across public cohorts identifies SLC35A2 as the only markedly upregulated solute carrier family member in tumors, linked to worse relapse-free survival in patients with high expression. Enrichment analyses connect SLC35A2 elevation to MYC-related and metabolic pathways, and CRC models indicate roles in tumor promotion and irinotecan chemoresistance, alongside reduced immune-cell infiltration and potential immunomodulation. Together, SLC35A2 may serve as a prognostic marker and therapeutic target in CRC.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/solute-carrier-family-35-a2-slc35a2-promotes-tumor-progression-through-myc-mediated-pathways-in-colorectal-cancer/370495/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/solute-carrier-family-35-a2-slc35a2-promotes-tumor-progression-through-myc-mediated-pathways-in-colorectal-cancer/370495.png","ImageObject",300,407,{"name":42,"@type":43},"Jacob","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main research goal of this CRC study?","Question",{"text":63,"@type":64},"The study investigates the therapeutic and prognostic implications of solute carrier family 35 A (SLC35A) members in colorectal cancer, with emphasis on the role of SLC35A2.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do the authors identify SLC35A2 as important in CRC?",{"text":68,"@type":64},"Integrative bioinformatics across multiple public databases compares CRC tumor tissues with adjacent normal tissues, showing only SLC35A2 is significantly upregulated while other family members decrease.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence links high SLC35A2 to patient outcomes and treatment response?",{"text":72,"@type":64},"High SLC35A2 expression is associated with poorer relapse-free survival, and CRC cell models indicate SLC35A2 upregulation correlates with chemoresistance to irinotecan.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370495,1790303099,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Ivyspring  \nInternational Publisher  \nInternationalJournal of Medical Sciences  \n2025; 22(9): 1992-2009. doi: 10.7150/ijms.109767  \nResearch Paper  \nSolute Carrier Family 35 A2 (SLC35A2) Promotes Tumor Progression through MYC-Mediated Pathways in Colorectal Cancer  \nKuei-Yen Tsai1,2,3, Po-Li Wei2,4,5,6, Cheng-Chin Lee1, Crystal Ngofi Zumbi1, G. M. Shazzad Hossain Prince1, Uyanga Batzorig7, Chien-Yu Huang8,9,10\\#􀀍, Yu-Jia Chang1,5,10,11,12\\#􀀍  \n1. Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.  \n2. Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.  \n3. Division of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235041, Taiwan.  \n4. Division of Colorectal Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan.  \n5. Cancer Research Center and Translational Laboratory, Department of Medical Research, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan.  \n6. Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei 11031, Taiwan.  \n7. Department of Dermatology, University of California, San Diego, La Jolla, CA 92093, USA.  \n8. School of Medicine, National Tsing Hua University, Hsinchu 300044, Taiwan.  \n9. Institute of Molecular and Cellular Biology, National Tsing Hua University 300044, Hsinchu, Taiwan.  \n10. Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.  \n11. Cell Physiology and Molecular Image Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.  \n12. Graduate Institue of Medical Sciences, National Defense Medical Center, Taipei 114201, Taiwan  \n\\# Authors contributed equally.  \n􀀍 Corresponding authors: 101, Section 2, Kuang-Fu Road, Hsinchu 300044, Taiwan R.O.C, Tel./Fax: 03-5715131 \\#35991 E-mail: Chien-Yu Huang: [cyhuang@life.nthu.edu.tw](cyhuang@life.nthu.edu.tw); Yu-Jia Chang: [r5424012@tmu.edu.tw](r5424012@tmu.edu.tw).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2025.01.02; Accepted: 2025.03.13; Published: 2025.03.29  \nAbstract  \nColorectal cancer (CRC) is one of the most prevalent cancers, posing a significant threat to human life. Although therapeutic approaches for advanced-stage patients have improved in recent years, there is still room for enhancing treatment response. Recent evidence suggests that dysregulation of nucleotide sugar transporters (NSTs) is associated with the development and progression of tumors. Therefore, this study aims to explore the potential therapeutic and prognostic implications of the solute carrier family 35 A (SLC35A) members in CRC. To achieve this, we performed integrative bioinformatics analysis using various publicly available databases, including GENT2, TCGA, UALCAN, cBioPortal, Kaplan-Meier plotter, The ROC plotter, GDSC, TISIDB, and TIMER. We compared gene expression profiles between CRC tumors and adjacent normal tissues, revealing that only SLC35A2 exhibited significant upregulation in tumors, while the other family members were downregulated. Additionally, higher SLC35A2 expression was found in microsatellite stable (MSS) colorectal tumors. Further analysis of TCGA and GEO datasets showed that patients with high SLC35A2 expression experienced poorer relapse-free survival. Next, we conducted gene set enrichment analysis (GSEA), and the results indicated that the upregulation of SLC35A2 is linked to cellular metabolism pathways, such as MYC Targets V2, Steroid Biosynthesis, Pentose Phosphate Pathway, and TCA Cycle. Furthermore, our CRC cell ","cbCaihg3COsNiKTm","https://ap.wps.com/l/cbCaihg3COsNiKTm","pdf",9639262,18,"English","# Abstract\n## Background and Aim\n## Methods (Integrative Bioinformatics)\n## Key Findings (Expression, Survival, Pathways)\n## Functional Evidence (Cell Models and Chemoresistance)\n## Immune Infiltration and Interpretation\n## Conclusion and Implications","[{\"question\":\"What is the main research goal of this CRC study?\",\"answer\":\"The study investigates the therapeutic and prognostic implications of solute carrier family 35 A (SLC35A) members in colorectal cancer, with emphasis on the role of SLC35A2.\"},{\"question\":\"How do the authors identify SLC35A2 as important in CRC?\",\"answer\":\"Integrative bioinformatics across multiple public databases compares CRC tumor tissues with adjacent normal tissues, showing only SLC35A2 is significantly upregulated while other family members decrease.\"},{\"question\":\"What evidence links high SLC35A2 to patient outcomes and treatment response?\",\"answer\":\"High SLC35A2 expression is associated with poorer relapse-free survival, and CRC cell models indicate SLC35A2 upregulation correlates with chemoresistance to irinotecan.\"}]","Solute Carrier Family 35 A2 (SLC35A2) Promotes Tumor Progression through MYC-Mediated Pathways in Colorectal Cancer | PDF",1790188811,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f949c2fef671b1290163991e60c36d4d.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f42630c36d024ec9f445ddc9322ab69f.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c088abd2d6722bbc4daaf6add6cfb77f.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ded4b1797b977b569265f9eec17b827a.webp",980,1268]